Form 4 Filing for Candel Therapeutics, Inc. - Insider Transaction

This filing details a Form 4 submitted by Mark E. Sims, Chief Commercial Officer of Candel Therapeutics, Inc. On July 6, 2026, Mr. Sims was granted 285,000 stock options to purchase Common Stock at an exercise price of $10.03 per share. These options vest over time, with 25% becoming exercisable on July 6, 2027, and the remainder vesting in equal monthly installments over the following 36 months, contingent upon continued service. The options expire on July 6, 2036. This transaction is classified as an acquisition of securities under the reporting code "A".